eFFECTOR Therapeutics' Series C Round

eFFECTOR Therapeutics raised a round of funding on July 24, 2017.

eFFECTOR Therapeutics is an early stage company focused on the discovery and development of new small molecule cancer therapeutics. eFFECTOR is developing translation regulators to selectively block d…

Articles about eFFECTOR Therapeutics' Series C Round: